Our analysis also gave BCL2 inhibitors associated with SF1126 or sirolimus (both MTOR inhibitors), and this combination of BCL2 with MTOR inhibitors is used in resistant acute lymphoblastic leukemia [36]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.